Availability of and challenges to resistance testing for second-line drugs, including the new and repurposed TB drugs
The Union
9/24/20, 5:00 PM
Europe/Paris GMT+2
Description
The session will report on the survey of Union members and members of Global Drug Initiative (GDI) and Global Laboratory Initiative (GLI) about the availability of drug susceptibility testing (DST), followed by a discussion of potential strategies to expand this availability.
Facilitator: Dr Alaine Umubyeyi Nyaruhirira, Management Sciences for Health, South Africa
Speakers:
Topic 1: Results of the 2020 DR-TB WG/GDI/GLI Survey, Dr Robert Horsburgh, Boston University, USA
Topic 2: Availability of and challenges to resistance testing for second-line drugs; a laboratory perspective, Dr Daniela Cirillo, Milan Supranational Reference Laboratory, Italy
Response: Availability of and challenges to resistance testing for second-line drugs; a programmatic perspective, Dr Fraser Wares, KNCV, The Netherlands
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Alaine Umubyeyi Nyaruhirira
Results of the 2020 DR-TB WG/GDI/GLI Survey, Availability of and challenges to resistance testing for second-line drugs; a laboratory perspective, Response: Availability of and challenges to resistance testing for second-line drugs; a programmatic perspective
Inglês
Speakers
Robert Horsburgh, Daniela Cirillo, Fraser Wares
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.